Adaptable Relief for Atopic Dogs and Cats. Manage the long-term cause with Cyclavance®
Cyclavance® is a potent 100mg/ml ciclosporin solution, equally as effective as capsules.
Product features & benefits:
Control of the Home Environment in Contributing to the Successful Management of Skin Disease
In this day and age we are blessed with many drugs to treat the cause and symptoms of allergic dermatitis which often results in topical treatments and simple environmental management routines are often not discussed with pet owners.
What Can Pet Owners Do at Home to Contribute to the Successful Management of Skin Disease?
Vets are very fortunate to have some outstanding medicines to treat the aetiology and clinical signs of atopy, giving both the pet and the owner relief from the angst of allergic skin disease. However, it is easy to overlook the value of topical therapies and simple environmental management routines, which can play an important role in managing the condition whilst also helping to cultivate client relationships.
Cyclavance is a 100mg/ml ciclosporin oral solution for cats and dogs with a 6 month shelf life once broached. Cyclavance allows accurate dosing to the nearest kg in one easy administration which limits the risks and inefficiencies of under and overdosing.
Treatment of chronic manifestations of atopic dermatitis in dogs and, in cats, symptomatic treatment of chronic allergic dermatitis.
In dogs = 5mg/kg & in Cats = 7mg/kg daily. Once clinical signs are improving the dosing frequency can be reduced to every other day or less frequently.
The product can be applied directly into the mouth or given with a small amount of food to ensure the whole dose is consumed.
Usually clinical signs are improving between 4 to 8 weeks after the course has been started but may be sooner depending on concurrent medications and allergy control.
It is common for the oily excipient to cause some gastrointestinal upsets such as vomiting and diarrhea. They are mild and transient and generally do not require the cessation of the treatment. Other side effects are listed on the datasheet and include symptoms like lethargy and inappetence. Reducing the dose or frequency of application can control these adverse effects.
While ciclosporin does not induce tumours, it does inhibit T-lymphocytes and therefore treatment with ciclosporin may lead to an increased incidence of clinically apparent malignancy due to the decrease in anti-tumour immune response. Lymphadenopathy observed on treatment with ciclosporin should be regularly monitored. There is thus a potentially increased risk of tumour progression if the tumour is already present before or occurs during the treatment with Cyclavance. This risk must be weighed against the clinical benefit.
A jelly-like formation may occur below 15°C which is however reversible at temperatures up to 25°C without affecting the quality of the product. After first opening, Cyclavance should be stored at room temperature between 15°C and 25°C.